TTP vs Phillips-Medisize: full comparison for 2026
Quick verdict
TTP (4.4/5) edges ahead of Phillips-Medisize (3.9/5) overall. TTP is the better choice for pharma device programs, inhalers and injectors. Phillips-Medisize is the stronger option for drug delivery devices needing high-volume production. The right choice depends on your project size, budget, and required tech stack.
TTP vs Phillips-Medisize: head-to-head summary
| Criterion | TTP | Phillips-Medisize |
|---|---|---|
| Founded | 1987 | 1964 |
| HQ | Melbourn, Cambridgeshire, UK | Hudson, WI, USA |
| Team size | Not published | ~7,000 |
| Rating | 4.4 / 5 | 3.9 / 5 |
| Primary differentiator | Employee ownership plus long-running drug delivery and surgical device work for large pharma and medtech clients | Design, molding and assembly of drug delivery devices under one global quality system |
| Pricing model | Time and materials, phased fixed project | Development contract plus manufacturing supply agreement |
| Min. engagement | Not disclosed | Not disclosed |
| Primary tech stack | Ultrasound, Microfluidics, Embedded C/C++ | Injection molding, Automated assembly, BLE |
| Industries served | Drug delivery, Surgical & robotics, Diagnostics & lab devices | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
TTP vs Phillips-Medisize: overview
TTP
TTP (The Technology Partnership) has operated for around 40 years from its own science park in Melbourn, South Cambridgeshire. In December 2021 TTP Group moved to 100% employee ownership through an Employee Ownership Trust. Its Medical Devices team works on drug delivery, surgical systems and diagnostics, and the wider company does deep technology work in sectors such as life science instruments and industrial products. Headcount is not published in a form we could verify.
Phillips-Medisize
Phillips-Medisize is a subsidiary of Molex, itself owned by Koch Industries, and provides outsourced design, development and manufacturing to pharma, diagnostics and medical device companies. It is based in Wisconsin and has about 7,000 employees. Molex's purchase of inhalation specialist Vectura added combination-product expertise, and the combined team includes more than 1,200 engineers and scientists across 30 sites. A $110M manufacturing campus in Katowice, Poland, opened in November 2023.
Services and capabilities: TTP vs Phillips-Medisize
| Capability | TTP | Phillips-Medisize |
|---|---|---|
| Electronics & PCB design | ✓ | ✓ |
| Firmware & embedded software | ✓ | ✗ |
| SaMD & companion apps | ✗ | ✗ |
| Connected devices & IoT | ✗ | ✗ |
| Industrial design & human factors | ✗ | ✗ |
| Mechanical engineering | ✓ | ✓ |
| Device cybersecurity | ✗ | ✗ |
| Regulatory & QMS support | ✓ | ✓ |
| Manufacturing & scale-up | ✗ | ✓ |
Tech stack comparison: TTP vs Phillips-Medisize
| Framework / platform | TTP | Phillips-Medisize |
|---|---|---|
| Embedded C/C++ | ✓ | N/A |
| Embedded Linux | N/A | N/A |
| RTOS | N/A | N/A |
| BLE | N/A | ✓ |
| Cloud (AWS/Azure) | N/A | N/A |
| IEC 62304 | N/A | N/A |
| ISO 14971 | N/A | N/A |
| ISO 13485 QMS | ✓ | ✓ |
| Qt | N/A | N/A |
Pricing comparison: TTP vs Phillips-Medisize
| Criterion | TTP | Phillips-Medisize |
|---|---|---|
| Minimum engagement | Not disclosed | Not disclosed |
| Engagement models | Consulting, Fixed project, Time & materials | Fixed project, Manufacturing contract |
| Rate transparency | Not public | Not public |
| Price tier | Mid-market | Mid-market |
Target audience comparison: TTP vs Phillips-Medisize
| Dimension | TTP | Phillips-Medisize |
|---|---|---|
| Best company size | Startup to mid-market | Startup to mid-market |
| Best industries | Drug delivery, Surgical & robotics, Diagnostics & lab devices | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
| Best use cases | Designing an autoinjector or inhaler for a pharma combination product, Developing a surgical energy device | Autoinjector or pen injector development and production, Inhaler device for a pharma combination product |
| Typical project type | Consulting | Fixed project |
TTP vs Phillips-Medisize: pros and cons
| TTP | |
|---|---|
| + | Employee ownership since 2021 removes pressure from outside investors |
| + | Well regarded for drug delivery devices, an area where mechanics and human factors decide success |
| + | Own science park with lab and workshop space for physical prototyping |
| + | Specialist depth in ultrasound and fluidics |
| - | Does not publish headcount or rates, which makes early budgeting harder |
| - | UK-centric delivery; US clients work across time zones |
| - | Pricing sits with the premium Cambridge consultancies |
| Phillips-Medisize | |
|---|---|
| + | Very large manufacturing footprint across the US, Europe and Asia |
| + | Vectura deal added deep inhalation and combination-product skills |
| + | Development and manufacturing under one quality system |
| + | Experience with connected drug delivery |
| - | Owned by Molex and Koch Industries, so it suits large pharma more than small startups |
| - | Development work is usually tied to a manufacturing agreement |
| - | Less suited to software-heavy or early research projects |
Who should choose TTP?
A typical fit: designing an autoinjector or inhaler for a pharma combination product.
Employee ownership plus long-running drug delivery and surgical device work for large pharma and medtech clients. Minimum engagement is not publicly disclosed. Works best with clients in Drug delivery, Surgical & robotics, Diagnostics & lab devices.
Who should choose Phillips-Medisize?
A typical fit: autoinjector or pen injector development and production.
Design, molding and assembly of drug delivery devices under one global quality system. Minimum engagement is not publicly disclosed. Works best with clients in Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices.
Decision matrix: TTP vs Phillips-Medisize
| Your situation | Recommended choice |
|---|---|
| You need full-ownership delivery on a defined project scope | TTP |
| You need a large dedicated team for an ongoing programme | Check each company's engagement model |
| Your budget is at the lower end | Compare: TTP (Not disclosed) vs Phillips-Medisize (Not disclosed) |
| You need specialist depth in a specific vertical | TTP |
| You need staff augmentation or team extension | Neither; consider alternatives that offer staff aug |
| You need consulting before committing to a build | Both may offer discovery engagements |
Use case fit: TTP vs Phillips-Medisize
| Use case | TTP fit | Phillips-Medisize fit | Winner |
|---|---|---|---|
| Designing an autoinjector or inhaler for a pharma combination product | Strong | Limited | TTP |
| Developing a surgical energy device | Strong | Limited | TTP |
| Autoinjector or pen injector development and production | Strong | Strong | Both equally |
| Inhaler device for a pharma combination product | Strong | Strong | Both equally |
Verdict: TTP vs Phillips-Medisize
TTP (4.4/5) is the stronger overall choice for most Medical Device Development projects. Employee ownership plus long-running drug delivery and surgical device work for large pharma and medtech clients.
Phillips-Medisize (3.9/5) is worth a look if you need inhaler device for a pharma combination product. If your situation matches that, Phillips-Medisize is a competitive option.
Related comparisons
TTP vs Phillips-Medisize FAQ
Is TTP better than Phillips-Medisize?
TTP (4.4/5) scores higher overall, but "better" depends on your use case. TTP's strongest advantage: employee ownership since 2021 removes pressure from outside investors. Phillips-Medisize's strongest advantage: very large manufacturing footprint across the US, Europe and Asia.
How do TTP and Phillips-Medisize differ in pricing?
TTP uses time and materials, phased fixed project pricing. Phillips-Medisize uses development contract plus manufacturing supply agreement pricing. Neither firm publishes a full rate card; a discovery call is required for project-specific quotes.
Which is better for enterprise: TTP or Phillips-Medisize?
Phillips-Medisize is the larger team and typically the better enterprise-scale choice. For very large programmes, verify team size and compliance coverage directly with each company before shortlisting.
What are the main differences between TTP and Phillips-Medisize?
TTP's primary differentiator is: employee ownership plus long-running drug delivery and surgical device work for large pharma and medtech clients. Phillips-Medisize's primary differentiator is: Design, molding and assembly of drug delivery devices under one global quality system. They also differ in team size (Not published vs ~7,000), minimum engagement (Not disclosed vs Not disclosed), and primary industries served (Drug delivery, Surgical & robotics vs Drug delivery, Diagnostics & lab devices).
Verify all details directly with each company before making a decision.